Inhaled antibiotics for lower airway infections

Annals of the American Thoracic Society

Volumn 11, Issue 3, 2014, Pages 425-434

  Quon, Bradley S ^a   Goss, Christopher H ^b   Ramsey, Bonnie W ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol; Inhaled antibiotics; Lower airway infection

Indexed keywords

AEROVANC; AMIKACIN; AMPHOTERICIN; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ARIKACE; AZTREONAM; AZTREONAM LYSINE; CAPREOMYCIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; FLUCONAZOLE; FOSFOMYCIN; GENTAMICIN; ISONIAZID PLUS RIFAMPICIN; LEVOFLOXACIN; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG; AMPHOTERICIN B; ANTIINFECTIVE AGENT;

AEROSOL; ANTIBIOTIC RESISTANCE; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; BRONCHOSPASM; CHEMICAL COMPOSITION; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG APPROVAL; DRUG CAPSULE; DRUG FORMULATION; DRUG MARKETING; DRY POWDER; DRY POWDER INHALER; DYSPNEA; GRAFT INFECTION; HEARING IMPAIRMENT; HUMAN; INJECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG DISEASE; MYCOBACTERIOSIS; NEBULIZATION; NEBULIZER; NONHUMAN; OFF LABEL DRUG USE; PSEUDOMONAS INFECTION; REVIEW; TASTE DISORDER; THROAT IRRITATION; TINNITUS; VENTILATOR ASSOCIATED PNEUMONIA; WHEEZING; COMPLICATION; INHALATIONAL DRUG ADMINISTRATION; PATHOLOGY; RESPIRATORY TRACT INFECTIONS;

ADMINISTRATION, INHALATION; AMIKACIN; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; AZTREONAM; CEFTAZIDIME; COLISTIN; CYSTIC FIBROSIS; GENTAMICINS; HUMANS; NEBULIZERS AND VAPORIZERS; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN;

EID: 84898730884     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201311-395FR     Document Type: Review

References (76)

1. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001;120:94S-98S. (Pubitemid 32881570)
2. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746. (Pubitemid 23170123)
3. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al.; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30. (Pubitemid 29024680)
4. Rose LM, Neale R. Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci Transl Med 2010;2:mr4.
5. Heijerman H, Westerman E, Conway S, Touw D, Döring G; Consensus Working Group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295 -315.
6. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-479.
7. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al.; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969. (Pubitemid 350127838)
8. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-689.
9. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-928.
10. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-1232.
11. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-1134.
12. Döring G, Hoiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91. (Pubitemid 38987019)
13. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011;3:CD001021.
14. Schuster A, Haliburn C, Döring G, Goldman MH; Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68:344-350.
15. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183:1510-1516.
16. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE, Phase FTISG; Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012;185:171-178.
17. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
18. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-856.
19. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al.; Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849. (Pubitemid 36801771)
20. Ratjen F, Munck A, Kho P, Angyalosi G, Group ES; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-291.
21. Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gérardin M, Brahimi N, Navarro J, Bingen E. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-292. (Pubitemid 32938877)
22. Ryan G, Jahnke N, Remmington T. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012;12:CD008319.
23. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
24. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-485. (Pubitemid 30647187)
25. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44. (Pubitemid 40052376)
26. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183:491-499.
27. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-817.
28. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B. Cipro floxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41:1107-1115.
29. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60:1216-1226. (Pubitemid 350168316)
30. Smith CR, Baughman KL, Edwards CQ, Rogers JF, Lietman PS. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977;296:349-353. (Pubitemid 8047169)
31. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
32. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ; Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184:106-115.
33. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65:2645-2649.
34. Falagas ME, Siempos II, Bliziotis IA, Michalopoulos A. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10:R123.
35. Klick JM, du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis: II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 1975;55:514-519.
36. Nunley DR, Grgurich W, Iacono AT, Yousem S, Ohori NP, Keenan RJ, Dauber JH. Allograft colonization and infections with Pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998;113:1235-1243. (Pubitemid 28223810)
37. Ruiz I, Gavaldà J, Monforte V, Len O, Román A, Bravo C, Ferrer A, Tenorio L, Román F, Maestre J, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006;6:178-182. (Pubitemid 43382216)
38. Suhling H, Rademacher J, Greer M, Haverich A, Warnecke G, Gottlieb J, Welte T. Inhaled colistin following lung transplantation in colonised cystic fibrosis patients. Eur Respir J 2013;42:542-544.
39. Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008;14:211-218. (Pubitemid 351572322)
40. Minari A, Husni R, Avery RK, Longworth DL, DeCamp M, Bertin M, Schilz R, Smedira N, Haug MT, Mehta A, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002;4:195-200. (Pubitemid 36142805)
41. Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients? Curr Opin Infect Dis 2013;26:317-325.
42. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-237. (Pubitemid 38155752)
43. Monforte V, Ussetti P, Gavaldà J, Bravo C, Laporta R, Len O, García-Gallo CL, Tenorio L, Solé J, Román A. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010;29:523-530.
44. Reichenspurner H, Gamberg P, Nitschke M, Valantine H, Hunt S, Oyer PE, Reitz BA. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997;29:627-628. (Pubitemid 27123555)
45. Hadjiliadis D, Howell DN, Davis RD, Lawrence CM, Rea JB, Tapson VF, Perfect JR, Palmer SM. Anastomotic infections in lung transplant recipients. Ann Transplant 2000;5:13-19.
46. Palmer SM, Perfect JR, Howell DN, Lawrence CM, Miralles AP, Davis RD, Tapson VF. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998;17:1029-1033. (Pubitemid 28499035)
47. Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 2011;91:71-81.
48. Philley JV, Griffith DE. Management of nontuberculous mycobacterial (NTM) lung disease. Semin Respir Crit Care Med 2013;34:135-142.
49. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17:955-961.
50. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 2007;32:140-150. (Pubitemid 47285721)
51. Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int J Pharm 2006;311:172-181.
52. Li Z, Zhang Y, Wurtz W, Lee JK, Malinin VS, Durwas-Krishnan S, Meers P, Perkins WR. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21:245-254.
53. Olivier K, Shaw P, Glaser T, Bhattacharyya D, Fleshner M, Brewer C, Zalewski C, Folio L, Siegelman J, Shallom S, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014;11:30-35.
54. Sethi S, Rennard MM, Martinez FJ, Donohue JF, Anzueto A, Grossman R, Loutit J, Dudley MN. A phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (mp-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients [abstract]. Am J Respir Crit Care Med 2012:A3037.
55. Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 2008;25:1019-1030.
56. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009;22:154-158.
57. Hubert D, Aubourg F, Fauroux B, Trinquart L, Sermet I, Lenoir G, Clément A, Dinh-Xuan AT, Louis B, Mahut B, et al. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments. Eur Respir J 2009;34:117-124.
58. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv 2011;24:175-182.
59. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, Weers JG. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124:360-366. (Pubitemid 36851374)
60. Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton RC, Pickford M, Hirst PH, et al. Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder. Pharm Res 2002;19:689-695. (Pubitemid 34553679)
61. Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol 2011;46:230-238.
62. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61.
63. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61:859-868. (Pubitemid 351426071)
64. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al.; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68:818-825.
65. Pai VB, Nahata MC. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr Pulmonol 2001;32:314-327. (Pubitemid 32938881)
66. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002;20:122-126. (Pubitemid 34822933)
67. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL, Group APIS; AZLI Phase II Study Group. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43:47-58.
68. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664.
69. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63. (Pubitemid 34114228)
70. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, Bitzan MM. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375-377. (Pubitemid 35192792)
71. Izquierdo MJ, Gomez-Alamillo C, Ortiz F, Calabia ER, Ruiz JC, de Francisco AL, Arias M. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 2006;66:464-467. (Pubitemid 44896157)
72. Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT, Thibert JM. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79:1185-1191. (Pubitemid 39129483)
73. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011;66:2398-2404.
74. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196. (Pubitemid 29196500)
75. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012;47:44-52.
76. Cystic Fibrosis Foundation. Drug development pipeline [accessed 25 Feb 2014]. Available from: http://www.cff.org/treatments/Pipeline